Pfizer launched the VESPER-6 Phase 3 clinical trial for its weight-loss drug candidate, berobenatide. The study evaluates the safety and efficacy of a once-monthly injection in overweight or obese adults. It is a randomized, double-blind, placebo-controlled study. The trial expects to enroll approximately 950 participants.
This move signals Pfizer's intensified efforts to compete in the lucrative obesity treatment market. Eli Lilly and Novo Nordisk currently dominate this market. A once-monthly injectable could offer a convenience advantage over existing weekly treatments. The VESPER-6 trial is part of a larger berobenatide program. This program includes multiple late-stage studies planned for 2026.